CN103717239B - 适合于吸入的氧化抗生物素蛋白的药物组合物 - Google Patents
适合于吸入的氧化抗生物素蛋白的药物组合物 Download PDFInfo
- Publication number
- CN103717239B CN103717239B CN201280037217.9A CN201280037217A CN103717239B CN 103717239 B CN103717239 B CN 103717239B CN 201280037217 A CN201280037217 A CN 201280037217A CN 103717239 B CN103717239 B CN 103717239B
- Authority
- CN
- China
- Prior art keywords
- biotinylation
- oxavidin
- lung
- avidin
- oxidized avidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
- A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Cell Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11006338 | 2011-08-02 | ||
| EP11006338.5 | 2011-08-02 | ||
| PCT/EP2012/064576 WO2013017494A1 (en) | 2011-08-02 | 2012-07-25 | Pharmaceutical composition of oxidised avidin suitable for inhalation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103717239A CN103717239A (zh) | 2014-04-09 |
| CN103717239B true CN103717239B (zh) | 2017-08-01 |
Family
ID=46581966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280037217.9A Active CN103717239B (zh) | 2011-08-02 | 2012-07-25 | 适合于吸入的氧化抗生物素蛋白的药物组合物 |
Country Status (19)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2941243A4 (en) | 2013-01-04 | 2016-09-14 | Massachusetts Inst Technology | SURFACE BINDING IN THE ADMINISTRATION OF A MEDICAMENT ON NANOPARTICLE BASE IN A TISSUE |
| EP3458097A4 (en) * | 2016-05-19 | 2020-01-08 | University of Miami | TARGETED DELIVERY OF THERAPEUTIC AGENTS AND IMAGING REAGENTS TO CANCER PANCREAS CELLS |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2106806A1 (en) * | 2008-03-31 | 2009-10-07 | Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. | Nanoparticles for targeted delivery of active agents to the lung |
| CN101772353A (zh) * | 2007-08-02 | 2010-07-07 | 希格马托制药工业公司 | 在受治疗组织中展现高停留时间的氧化的抗生物素蛋白 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5384128A (en) * | 1993-03-02 | 1995-01-24 | University Of Alabama Research Foundation | Method of and compounds for treatment for cystic fibrosis |
| WO1995003034A1 (en) | 1993-07-19 | 1995-02-02 | Amgen Inc. | Stabilization of aerosolized proteins |
| DE69830305T2 (de) * | 1997-02-20 | 2006-02-02 | Dime, David S., Toronto | Ortsspezifische arzneimittel verabreichung |
| EP1169053A1 (en) * | 1999-04-13 | 2002-01-09 | Inhale Therapeutic Systems, Inc. | Pulmonary administration of dry powder formulations for treating infertility |
| US7001994B2 (en) * | 2001-01-18 | 2006-02-21 | Genzyme Corporation | Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins |
| ITRM20010079A1 (it) | 2001-02-16 | 2002-08-16 | Sigma Tau Ind Farmaceuti | Amminoderivati della biotina e loro coniugati con chelanti macrociclici. |
| ITRM20030196A1 (it) * | 2003-04-24 | 2004-10-25 | Sigma Tau Ind Farmaceuti | Uso di reagenti per la preparazione di un medicamento |
| BRPI0517204A (pt) * | 2004-12-17 | 2008-09-30 | Cipla Ltd | sulfato de levosalbutamol cristalino (forma i), sulfato de levosalbutamol cristalino (forma ii), sulfato de levosalbutamol cristalino (forma iii), processo para preparar a forma i do sulfato de levosalbutamol cristalino, processo para preparar a forma ii do sulfato de levosalbutamol cristalino, processo para preparar a forma iii do sulfato de levosalbutamol, composição farmacêutica, composto, combinação, pó seco para inalador, processo para preparar um pó seco para inalador, processo para preparar uma composição famacêutica, processo para fabricação de uma composição farmacêutica, método para tratamento de um mamìfero, e uso de uma combinação de salbutamol |
| GB0602778D0 (en) * | 2006-02-10 | 2006-03-22 | Glaxo Group Ltd | Novel compound |
| TW201031436A (en) * | 2009-02-16 | 2010-09-01 | Univ Nat Taiwan | Pharmaceutical composition for inhalation delivery and fabrication method thereof |
-
2012
- 2012-07-25 EA EA201490401A patent/EA026453B1/ru not_active IP Right Cessation
- 2012-07-25 PH PH1/2014/500193A patent/PH12014500193A1/en unknown
- 2012-07-25 KR KR1020147001707A patent/KR101966630B1/ko active Active
- 2012-07-25 JP JP2014523289A patent/JP6019118B2/ja active Active
- 2012-07-25 DK DK12740137.0T patent/DK2739314T3/da active
- 2012-07-25 ES ES12740137T patent/ES2729549T3/es active Active
- 2012-07-25 CN CN201280037217.9A patent/CN103717239B/zh active Active
- 2012-07-25 MX MX2014001176A patent/MX355177B/es active IP Right Grant
- 2012-07-25 BR BR112014002593-2A patent/BR112014002593B1/pt not_active IP Right Cessation
- 2012-07-25 CA CA2842276A patent/CA2842276C/en active Active
- 2012-07-25 EP EP12740137.0A patent/EP2739314B1/en active Active
- 2012-07-25 PL PL12740137T patent/PL2739314T3/pl unknown
- 2012-07-25 WO PCT/EP2012/064576 patent/WO2013017494A1/en not_active Ceased
- 2012-07-25 PT PT12740137T patent/PT2739314T/pt unknown
- 2012-07-25 UA UAA201402021A patent/UA114482C2/uk unknown
- 2012-07-25 AU AU2012292229A patent/AU2012292229B2/en active Active
- 2012-07-25 US US14/236,445 patent/US9872831B2/en active Active
-
2014
- 2014-01-22 IL IL230597A patent/IL230597A0/en active IP Right Grant
- 2014-02-27 ZA ZA2014/01921A patent/ZA201401921B/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101772353A (zh) * | 2007-08-02 | 2010-07-07 | 希格马托制药工业公司 | 在受治疗组织中展现高停留时间的氧化的抗生物素蛋白 |
| EP2106806A1 (en) * | 2008-03-31 | 2009-10-07 | Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. | Nanoparticles for targeted delivery of active agents to the lung |
Non-Patent Citations (1)
| Title |
|---|
| Pretargeted Radioimmunotherapy of Cancer: Progress Step by Step;Otto C. Boerman et al.;《The Journal of Nuclear Medicine》;20030331;第44卷(第3期);第400-411页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012292229A1 (en) | 2014-02-13 |
| EP2739314B1 (en) | 2019-05-22 |
| WO2013017494A1 (en) | 2013-02-07 |
| PL2739314T3 (pl) | 2019-09-30 |
| UA114482C2 (uk) | 2017-06-26 |
| CA2842276A1 (en) | 2013-02-07 |
| CA2842276C (en) | 2020-11-24 |
| KR20140047668A (ko) | 2014-04-22 |
| MX2014001176A (es) | 2014-07-14 |
| US9872831B2 (en) | 2018-01-23 |
| EA201490401A1 (ru) | 2014-05-30 |
| AU2012292229B2 (en) | 2017-08-03 |
| JP6019118B2 (ja) | 2016-11-02 |
| DK2739314T3 (da) | 2019-06-24 |
| IL230597A0 (en) | 2014-03-31 |
| MX355177B (es) | 2018-04-09 |
| JP2014521675A (ja) | 2014-08-28 |
| PT2739314T (pt) | 2019-06-21 |
| BR112014002593A2 (pt) | 2017-03-01 |
| KR101966630B1 (ko) | 2019-04-09 |
| ES2729549T3 (es) | 2019-11-04 |
| ZA201401921B (en) | 2015-05-27 |
| BR112014002593B1 (pt) | 2022-11-29 |
| US20140134106A1 (en) | 2014-05-15 |
| CN103717239A (zh) | 2014-04-09 |
| EA026453B1 (ru) | 2017-04-28 |
| PH12014500193A1 (en) | 2014-03-24 |
| NZ620202A (en) | 2016-05-27 |
| EP2739314A1 (en) | 2014-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | Nanomedicine embraces cancer radio-immunotherapy: mechanism, design, recent advances, and clinical translation | |
| CN111989138B (zh) | 人源化抗前列腺特异性膜抗原(psma)抗体药物缀合物 | |
| Groneberg et al. | Molecular mechanisms of pulmonary peptidomimetic drug and peptide transport | |
| US20070231408A1 (en) | Colloidal metal compositions and methods | |
| US20110064652A1 (en) | Nanoparticles for targeted delivery of active agents to the lung | |
| CN111954531A (zh) | α聚谷氨酸化培美曲塞及其用途 | |
| CN111954529A (zh) | α聚谷氨酸化氨甲蝶呤及其用途 | |
| CN111936146A (zh) | α聚谷氨酸化四氢叶酸及其用途 | |
| Maillet et al. | The airways, a novel route for delivering monoclonal antibodies to treat lung tumors | |
| RS61961B1 (sr) | Morfogenetski proteini kosti | |
| Aggarwal et al. | Pulmonary Fibrosis: Unveiling the pathogenesis, exploring therapeutic targets, and advancements in drug delivery strategies | |
| CN103717239B (zh) | 适合于吸入的氧化抗生物素蛋白的药物组合物 | |
| Zarogoulidis et al. | 2-diethylaminoethyl-dextran methyl methacrylate copolymer nonviral vector: still a long way toward the safety of aerosol gene therapy | |
| CN118766874B (zh) | 一种吸入式制剂、迭代优化流程及其应用 | |
| JP2001512831A (ja) | 生物学的薬剤組成物を同定する方法 | |
| HK1194002A (en) | Pharmaceutical composition of oxidised avidin suitable for inhalation | |
| HK1194002B (en) | Pharmaceutical composition of oxidised avidin suitable for inhalation | |
| NZ620202B2 (en) | Pharmaceutical composition of oxidised avidin suitable for inhalation | |
| US10912791B2 (en) | Compositions comprising antisense-encoded erythropoietin receptor and use thereof | |
| EP4188433A2 (en) | Targeted delivery of therapeutic agents | |
| Siddhanta et al. | Inhalable perfluorocarbon RNA nanocapsules overcome biological barriers to treat lung metastases | |
| US20180177724A1 (en) | Site-targeted nano-liposomal nitroglycerin therapeutics | |
| Huayamares et al. | Current Research in Biotechnology | |
| CN121226499A (zh) | 一种多肽及其作为基因递送载体的应用 | |
| Gaber et al. | In vivo pharmacodynamics of lactoferrin-coupled lipid nanocarriers for lung carcinoma: intravenous versus powder for inhalation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1194002 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180118 Address after: Milan Italy Patentee after: Alpha Sigmar joint-stock company Address before: Rome Italy Patentee before: Sigma-Tau Industrie Farmaceutiche Riunite S. P. A. |
|
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: Bologna, Italy Patentee after: Alpha sigma Co., Ltd Address before: Milan Italy Patentee before: Alpha Sigmar JSC |